Cardiovascular events and deaths continue to increase worldwide
Cardiovascular disease (CVD) is the number one cause of death globally; more people die annually from CVD than from any other cause. 6 In addition to the global health burden, CVD also has a significant economic impact, estimated at €169 billion in the EU and $450 billion in the United States for direct and indirect annual costs.7,8 CVD accounts for 24% of all deaths globally each year1, and by 2030 the
.8 CVD is also becoming an increasing health concern in the developing world.2 A total of 80% of cardiovascular deaths
now occur in low-to-middle income countries, imposing an economic cost of over $3 trillion.2
LDL-C is a major risk factor for CVD
Too much LDL-C, or “bad” cholesterol, can increase the risk of heart disease and stroke.8
Cholesterol management guidelines continue to evolve
Reducing LDL-C to goal remains the primary focus when managing hypercholesterolemia, and LDL-C lowering with statins has been proven to be one of the most effective means of reducing the risk of CVD.10,11,12 A large number of randomized, controlled clinical trials, as well as the most recent Cholesterol Treatment Trialists’ Collaboration (CTT) meta-analysis involving >170,000 patients, have documented that lowering LDL-C levels can reduce the risk for major coronary events.13
To help better manage CVD, most current guidelines strongly recommend selecting LDL-C goals according to the level of a patient’s total CV risk.3 In the EU guidelines, patients with higher CV risk have a lower LDL-C goal than patients with lower CV risk.10 These patients are usually classified based on having a known history of CVD (e.g., previous heart attack, acute coronary syndrome) or a high risk for CVD (e.g., previous ischemic stroke, peripheral artery disease, or diabetes and target organ damage).
Cardiovascular disease (CVD) is the number one cause of death globally; more people die annually from CVD than from any other cause. 6 In addition to the global health burden, CVD also has a significant economic impact, estimated at €169 billion in the EU and $450 billion in the United States for direct and indirect annual costs.7,8 CVD accounts for 24% of all deaths globally each year1, and by 2030 the
.8 CVD is also becoming an increasing health concern in the developing world.2 A total of 80% of cardiovascular deaths
now occur in low-to-middle income countries, imposing an economic cost of over $3 trillion.2
LDL-C is a major risk factor for CVD
Too much LDL-C, or “bad” cholesterol, can increase the risk of heart disease and stroke.8
Cholesterol management guidelines continue to evolve
Reducing LDL-C to goal remains the primary focus when managing hypercholesterolemia, and LDL-C lowering with statins has been proven to be one of the most effective means of reducing the risk of CVD.10,11,12 A large number of randomized, controlled clinical trials, as well as the most recent Cholesterol Treatment Trialists’ Collaboration (CTT) meta-analysis involving >170,000 patients, have documented that lowering LDL-C levels can reduce the risk for major coronary events.13
To help better manage CVD, most current guidelines strongly recommend selecting LDL-C goals according to the level of a patient’s total CV risk.3 In the EU guidelines, patients with higher CV risk have a lower LDL-C goal than patients with lower CV risk.10 These patients are usually classified based on having a known history of CVD (e.g., previous heart attack, acute coronary syndrome) or a high risk for CVD (e.g., previous ischemic stroke, peripheral artery disease, or diabetes and target organ damage).
total direct medical
costs of CVD in the United States are projected to triple, from $273 billion to $818 billion
There are many types of cholesterol – the three most commonly referenced ones are:9
-
· Low density lipoprotein cholesterol (LDL-C) – often called "bad" cholesterol
-
· High density lipoprotein cholesterol (HDL-C) – often called "good" cholesterol
-
· Total cholesterol – all cholesterol levels combined
A high blood LDL-C level, or hypercholesterolemia, is a major risk factor for the development of CVD.2
Cardiovascular events and deaths continue to increase worldwide
Cardiovascular disease (CVD) is the number one cause of death globally; more people die annually from CVD than from any other cause. 6 In addition to the global health burden, CVD also has a significant economic impact, estimated at €169 billion in the EU and $450 billion in the United States for direct and indirect annual costs.7,8 CVD accounts for 24% of all deaths globally each year1, and by 2030 the
.8 CVD is also becoming an increasing health concern in the developing world.2 A total of 80% of cardiovascular deaths
now occur in low-to-middle income countries, imposing an economic cost of over $3 trillion.2
LDL-C is a major risk factor for CVD
Too much LDL-C, or “bad” cholesterol, can increase the risk of heart disease and stroke.8
Cholesterol management guidelines continue to evolve
Reducing LDL-C to goal remains the primary focus when managing hypercholesterolemia, and LDL-C lowering with statins has been proven to be one of the most effective means of reducing the risk of CVD.10,11,12 A large number of randomized, controlled clinical trials, as well as the most recent Cholesterol Treatment Trialists’ Collaboration (CTT) meta-analysis involving >170,000 patients, have documented that lowering LDL-C levels can reduce the risk for major coronary events.13
To help better manage CVD, most current guidelines strongly recommend selecting LDL-C goals according to the level of a patient’s total CV risk.3 In the EU guidelines, patients with higher CV risk have a lower LDL-C goal than patients with lower CV risk.10 These patients are usually classified based on having a known history of CVD (e.g., previous heart attack, acute coronary syndrome) or a high risk for CVD (e.g., previous ischemic stroke, peripheral artery disease, or diabetes and target organ damage).
Cardiovascular disease (CVD) is the number one cause of death globally; more people die annually from CVD than from any other cause. 6 In addition to the global health burden, CVD also has a significant economic impact, estimated at €169 billion in the EU and $450 billion in the United States for direct and indirect annual costs.7,8 CVD accounts for 24% of all deaths globally each year1, and by 2030 the
.8 CVD is also becoming an increasing health concern in the developing world.2 A total of 80% of cardiovascular deaths
now occur in low-to-middle income countries, imposing an economic cost of over $3 trillion.2
LDL-C is a major risk factor for CVD
Too much LDL-C, or “bad” cholesterol, can increase the risk of heart disease and stroke.8
Cholesterol management guidelines continue to evolve
Reducing LDL-C to goal remains the primary focus when managing hypercholesterolemia, and LDL-C lowering with statins has been proven to be one of the most effective means of reducing the risk of CVD.10,11,12 A large number of randomized, controlled clinical trials, as well as the most recent Cholesterol Treatment Trialists’ Collaboration (CTT) meta-analysis involving >170,000 patients, have documented that lowering LDL-C levels can reduce the risk for major coronary events.13
To help better manage CVD, most current guidelines strongly recommend selecting LDL-C goals according to the level of a patient’s total CV risk.3 In the EU guidelines, patients with higher CV risk have a lower LDL-C goal than patients with lower CV risk.10 These patients are usually classified based on having a known history of CVD (e.g., previous heart attack, acute coronary syndrome) or a high risk for CVD (e.g., previous ischemic stroke, peripheral artery disease, or diabetes and target organ damage).
total direct medical
costs of CVD in the United States are projected to triple, from $273 billion to $818 billion
There are many types of cholesterol – the three most commonly referenced ones are:9
-
· Low density lipoprotein cholesterol (LDL-C) – often called "bad" cholesterol
-
· High density lipoprotein cholesterol (HDL-C) – often called "good" cholesterol
-
· Total cholesterol – all cholesterol levels combined
A high blood LDL-C level, or hypercholesterolemia, is a major risk factor for the development of CVD.2
